Search, Find and Buy Antibodies, ELISA Kits and Proteins.
Loading Loading
Add to Basket
Order hotline:
phone +1 404 474 4654
fax +1 888 205 9894 (TF)
Details for Product No. ABIN152139

Chemokine (C-X-C Motif) Receptor 4 (CXCR4) antibody

Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

FB22, HM89, LAP3, LCR1, NPYR, WHIM, CD184, LESTR, NPY3R, NPYRL, HSY3RR, NPYY3R, D2S201E, Sdf1r, Cmkar4, PB-CKR, PBSF/SDF-1, CXCR4, cb403, zgc:109863, CXC-R4, CXCR-4, cd184, d2s201e, fb22, hm89, hsy3rr ... show more
»Alternatives Human
Clonality Polyclonal
»Alternatives Un-conjugated
»Alternatives Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB), ELISA
Pubmed 4 references available
Catalog no. ABIN152139
Quantity 0.1 mg
Contact our Customer Service for availability and price in your country.
Shipping to
Immunogen Synthetic peptide: TEEMGSGDYDSMKEPCFREENANFNKC (Human).
Specificity Peptide sequence is < 50 % identical to other human chemokine receptors in thisregionall. Species Reactivity: Cross-reacts with Human. Not yet tested in other species. Localization: Cell Membrane.
Cross-Reactivity Human
Purification Purified
Alternative Name CD184 / CXCR4
Background CXCR4 is a principal coreceptor for T cell tropic strains of HIV1 fusion and entry ofhuman white blood cells. CXCR4 is also required for the infection by dual-tropic strainsof HIV1 and mediates CD4 independent infection by HIV2. The a chemokine SDF1 isthe ligand for CXCR4 and prevents infection by T tropic HIV1. CXCR4 associates withthe surface CD4-gp120 complex before HIV enters target cells. CXCR4 messengerRNA levels correlated with HIV1 permissiveness in diverse human cell types. Antibodiesto CXCR4 block HIV1 and HIV2 fusion and infection of human target cells. The aminoterminal domain and the second extracellular loop of CXCR4 serve as HIV biding sites.CXCR4 is highly expressed in brain and heart, and in white blood cells, vascularendothelial cells, and umbilical cord endothelial cells. Alternate Names: anti-CD184 antibody, anti-Chemokine CXC Motif Receptor 4 antibody, anti-FB22antibody, anti-Fusin antibody, anti-HM89 antibody, anti-HSY3RR antibody, anti-LAP3antibody, anti-LCR1 antibody, anti-LESTR antibody, anti-NPY3R antibody, anti-NPYRantibody, anti-NPYRL antibody, anti-NPYY3 antibody, anti-NPYY3R antibody,anti-Probable G protein coupled receptor lcr1 homolog antibody, anti-WHIM antibody.
Gene ID 7852
Research Area CD Antigens, Surface Receptors of Immune Cells, Chemokines, Receptors
Application Notes Suggested working dilutions: ELISA 1:50000,Western Blot 1:1000,Immunocytochemistry 1:300,Immunohistochemistry-Paraffin 1:300. Positive Controls: Human peripheral blood cells or sections of human spleen cells.
Restrictions For Research Use only
Buffer PBS, 1mg/ml BSA,pH7.2. Preservative: 0.1% Sodium azide.
Preservative Sodium azide
Storage -20 °C
Loetscher, Geiser, OReilly et al.: "Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes." in: The Journal of biological chemistry, Vol. 269, Issue 1, pp. 232-7, 1994 (PubMed).

Bleul, Farzan, Choe et al.: "The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry." in: Nature, Vol. 382, Issue 6594, pp. 829-33, 1997 (PubMed).

Schimanski, Schwald, Simiantonaki et al.: "Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 11, Issue 5, pp. 1743-50, 2005 (PubMed).

Diomedi-Camassei, McDowell, De Ioris et al.: "Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, Issue 13, pp. 4119-27, 2008 (PubMed).

Alternatives for antigen "Chemokine (C-X-C Motif) Receptor 4 (CXCR4)", type "Antibodies"
Hosts (172), (42), (24), (12), (1)
Reactivities (214), (112), (64), (30), (16), (12), (6), (3), (3), (2), (2)
Applications (156), (79), (73), (70), (39), (27), (26), (24), (20), (9), (8), (6), (4), (3), (1), (1), (1)
Conjugates (5), (5), (4), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (51), (17), (11), (10), (8), (7), (6), (6), (6), (4), (4), (3), (3), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)